BACKGROUND: FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase involved in hematopoietic progenitor cell development. Mutations of FLT3 have been reported in about a third of patients with acute myeloid leukemia (AML), and inhibitors of FLT3 are of clinical interest. Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway. METHODS: We studied the patterns of molecular response and relapse in 18 patients with mutated FLT3 treated with the combination of sorafenib, idarubicin, and cytarabine. RESULTS: The median follow-up was 9 months. Sixteen patients achieved complete remission (CR), and the other 2 patients achieved CR but lacked platelet recovery for an overall response rate of 100%. Ten patients had their FLT3-mutated clone eradicated, with 6 patients who showed some residual FLT3-mutated cells, and 2 patients who showed persistent FLT3-mutated cells. The elimination of FLT3-mutated population at the time of morphologic CR, however, was not predictive of relapse. After a median follow-up of 9 months (range, 1-16 months), 10 (55%) patients had relapsed, with a median CR duration of 8.8 months (range, 1-9.5 months). By DNA sequencing, there was no evidence of an acquired FLT3 point mutation at the time of relapse in 7 patients tested, which suggested the presence of other mechanisms of sorafenib resistance. CONCLUSION: Sorafenib, combined with chemotherapy, is effective in attaining CR, but relapses still occur.
BACKGROUND:FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase involved in hematopoietic progenitor cell development. Mutations of FLT3 have been reported in about a third of patients with acute myeloid leukemia (AML), and inhibitors of FLT3 are of clinical interest. Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway. METHODS: We studied the patterns of molecular response and relapse in 18 patients with mutated FLT3 treated with the combination of sorafenib, idarubicin, and cytarabine. RESULTS: The median follow-up was 9 months. Sixteen patients achieved complete remission (CR), and the other 2 patients achieved CR but lacked platelet recovery for an overall response rate of 100%. Ten patients had their FLT3-mutated clone eradicated, with 6 patients who showed some residual FLT3-mutated cells, and 2 patients who showed persistent FLT3-mutated cells. The elimination of FLT3-mutated population at the time of morphologic CR, however, was not predictive of relapse. After a median follow-up of 9 months (range, 1-16 months), 10 (55%) patients had relapsed, with a median CR duration of 8.8 months (range, 1-9.5 months). By DNA sequencing, there was no evidence of an acquired FLT3 point mutation at the time of relapse in 7 patients tested, which suggested the presence of other mechanisms of sorafenib resistance. CONCLUSION:Sorafenib, combined with chemotherapy, is effective in attaining CR, but relapses still occur.
Authors: Hagop Kantarjian; Susan O'brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey Journal: Cancer Date: 2006-03-01 Impact factor: 6.860
Authors: Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich Journal: Blood Date: 2005-12-20 Impact factor: 22.113
Authors: Soheil Meshinchi; Todd A Alonzo; Derek L Stirewalt; Michel Zwaan; Martin Zimmerman; Dirk Reinhardt; Gertjan J L Kaspers; Nyla A Heerema; Robert Gerbing; Beverly J Lange; Jerald P Radich Journal: Blood Date: 2006-08-15 Impact factor: 22.113
Authors: Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe Journal: Blood Date: 2001-04-15 Impact factor: 22.113
Authors: Steven Knapper; Alan K Burnett; Tim Littlewood; W Jonathan Kell; Sam Agrawal; Raj Chopra; Richard Clark; Mark J Levis; Donald Small Journal: Blood Date: 2006-07-20 Impact factor: 22.113
Authors: F Ravandi; I Jilani; E Estey; H Kantarjian; A Dey; C Aguilar; C Jitkaroon; F Giles; S O'Brien; M Keating; M Albitar Journal: Leuk Res Date: 2006-12-06 Impact factor: 3.156
Authors: Susan P Whitman; Amy S Ruppert; Michael D Radmacher; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Frederick Racke; Bayard L Powell; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2007-10-16 Impact factor: 22.113
Authors: Adam J Mead; David C Linch; Robert K Hills; Keith Wheatley; Alan K Burnett; Rosemary E Gale Journal: Blood Date: 2007-04-24 Impact factor: 22.113
Authors: Stephen T Keir; John M Maris; Richard Lock; E Anders Kolb; Richard Gorlick; Hernan Carol; Christopher L Morton; C Patrick Reynolds; Min H Kang; Amy Watkins; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: Farhad Ravandi; Mona Lisa Alattar; Michael R Grunwald; Michelle A Rudek; Trivikram Rajkhowa; Mary Ann Richie; Sherry Pierce; Naval Daver; Guillermo Garcia-Manero; Stefan Faderl; Aziz Nazha; Marina Konopleva; Gautam Borthakur; Jan Burger; Tapan Kadia; Sara Dellasala; Michael Andreeff; Jorge Cortes; Hagop Kantarjian; Mark Levis Journal: Blood Date: 2013-04-23 Impact factor: 22.113